

Curriculum Vitae

Nome: Paba Pierpaolo

Data e Luogo di nascita: [REDACTED]
[REDACTED]

Cittadinanza: Italiana

Stato civile:

Indirizzo:

Storia professionale:

Luglio 2000-Gennaio 2001: Tirocinante presso il Laboratorio di Microbiologia dell'Ospedale "Fatebenefratelli San Giovanni Calibita" Isola Tiberina.

Febbraio 2001: Specializzando presso il Laboratorio di Microbiologia Clinica e Virologia del Policlinico Universitario "Tor Vergata" di Roma.

Dicembre 2002: Contrattista di ricerca presso L'Università di Roma "Tor Vergata" per il programma di ricerca:
"Infezione della cervice uterina da virus del Papilloma umano (HPV): identificazione di genotipi ad alto rischio ed espressione dei geni coinvolti nel processo di cancerogenesi"

Febbraio 2005: Consulente libero professionale presso il Laboratorio di Microbiologia e Virologia Clinica del Policlinico Universitario Tor Vergata

Marzo 2003-Luglio 2008 Consulente Libero professionale presso il Laboratorio "Labomedica" settore

Batteriologia e Micologia sito in viale Giulio Agricola, 33 00174 Roma

Luglio 2008:

Dirigente Biologo Convenzionato ai sensi dell'A.C.N. 23/05/2005 s.m.i. 38 ore settimanali presso il Laboratorio di Microbiologia e Virologia del Policlinico Universitario Tor Vergata di Roma.

Istruzione:

Diploma di Maturità Classica:	1994	Liceo Classico "Benedetto Da Norcia" Roma
Diploma di Laurea in Scienze Biologiche:	2000	Università di Roma "Tor Vergata"
Abilitazione all'esercizio professionale:	2001	Università di Roma "Tor Vergata"
Specializzazione in Microbiologia e Virologia:	2004	Università di Roma "Tor Vergata"

Società Scientifiche:

Membro dell'Associazione Microbiologi Clinici Italiani (Componente Gruppo di lavoro infezioni nel paziente trapiantato GLAIT)
Membro della Società Italiana di Virologia Medica

Conoscenza Lingua Straniera:

Inglese

Autore di 33 Lavori scientifici in extenso su riviste internazionali. Numerose sono le partecipazioni a Congressi Nazionali ed Internazionali.

Publicazioni:

1. Polyoma virus BK and renal dysfunction in a transplanted population. Splendiani G, Cipriani S, Condo S, **Paba P**, Ciotti M, Favalli C, Vega A, Dominijanni S, Casciani CU. *Transplant Proc.* 2004 Apr;36(3):713-5.
2. Branca, M., Ciotti M., Santini D., Di Bonito L., Benedetto A., Giorgi C., **Paba P.**, Favalli C., Costa S., Agarossi A., Alderisio M., and Syrjanen K. On behalf of the HPV-PathogenISS Study Group. Expression of p16^{INK4a} is a prognostic factor in cervical cancer, related to grade of CIN and high-risk human papillomavirus (HPV) but does not predict virus clearance after cone treatment. *Int. J. Gynaecological Pathology* 23(4):354-365, 2004.
3. Ciotti M., Sesti F., **Paba P.**, Benedetto A., Patrizi L., Criscuolo A., Favalli C., Piccione E., Branca M., Syrjänen K.. Human papillomavirus (HPV) testing in the management of women with abnormal pap smear. Experience from colposcopy referral clinic. *European Journal of Gynaecological Oncology* 25(5):577-584, 2004.
4. Branca M., Ciotti M., Santini D., Di Bonito L., Benedetto A., Giorgi C., **Paba P.**, Favalli C., Costa S., Agarossi A., Bonifacio D., Zanconati F., Alderisio M., and Syrjanen K. Activation of the ERK/MAP Kinase Pathway in Cervical Intraepithelial Neoplasia Is Related to Grade of the Lesion but not to High-Risk Human Papillomavirus, Virus Clearance, or Prognosis in Cervical Cancer. *Am. J. Clinical Pathology* 2004 Dec; 122(6):902-11.
5. Branca M., Costa S., Mariani L., Sesti F., Agarossi A., Di Carlo A., Galati M., Benedetto A., Ciotti M., Giorgi C., Criscuolo A., Valieri M., Favalli C., **Paba P.**, Santini D., Piccione E., Alderisio M., De Nuzzo M., Di Bonito L., and Syrjanen K.. Assessment of risk factors and Human Papillomavirus (HPV) related pathogenic mechanism of CIN in HIV-positive and HIV-negative women-Study Design and Baseline Data of the HPV-PathogenISS Study. *European Journal of Gynaecological Oncology* 2004; 25(6):689-98
6. Branca, M., Giorgi C., Santini D., Di Bonito L., Ciotti M., Costa S., Benedetto A., Casolari EA., Favalli C., **Paba P.**, Di Bonito P., Mariani L., Syrjanen S., Bonifacio

- D., Accardi L., Zanconati F., and Syrjanen K. On behalf of the HPV-PathogeneISS Study Group. Survivin as a marker of cervical intraepithelial neoplasia and high-risk human papillomavirus and a predictor of virus clearance and prognosis in cervical cancer. *Am. J. Clinical Pathology* 2005 Jul;124(1): 1-9.
7. Ciotti M., **Paba P.**, Bonifacio D., Di Bonito L., Benedetto A., Favalli C. Single or multiple HPV types in cervical cancer and associated metastases. *Oncol Rep.* 2006 Jan;15(1):143-8.
 8. Branca, M., Giorgi C., Santini D., Di Bonito L., Ciotti M., Benedetto A., **Paba P.**, Costa S., Bonifacio D., Di Bonito P., Accardi L., Favalli C., Agarossi A., Alderisio M., and Syrjanen K. On behalf of the HPV-PathogeneISS Study Group. Aberrant expression of vascular endothelial growth factor-c (vegf-c) is related to grade of cervical intraepithelial neoplasia (CIN) and high-risk human papillomavirus (HPV), but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer. *J. Clinical Pathology* 2006 Jan;59(1):40-7.
 9. Branca, M., Giorgi C., Ciotti M., Santini D., Di Bonito L., Costa S., Benedetto A., Bonifacio D., Di Bonito P., **Paba P.**, Accardi L., Syrjanen S., Favalli C., Syrjanen K. On behalf of the HPV-PathogeneISS Study Group. Relationship of Up-Regulation of 67-kd Laminin Receptor to Grade of Cervical Intraepithelial Neoplasia and to High-Risk HPV Types and Prognosis in Cervical Cancer. *Acta Cytologica* 2006 Gen-Feb 2006 50(1):6-15.
 10. Branca, M., Giorgi C., Ciotti M., Santini D., Di Bonito L., Costa S., Benedetto A., Bonifacio D., Di Bonito P., **Paba P.**, Accardi L., Mariani L., Ruutu M., Favalli C., Syrjanen K. On behalf of the HPV-PathogeneISS Study Group. Down-regulated nucleoside diphosphate (NDP) kinase nm23-h1 expression is unrelated to high-risk human papillomavirus (HPV) but associated with progression of cin and unfavourable prognosis in cervical cancer. *J Clin Pathol.* 2006 Oct;59(10):1044-51. Epub 2006 Mar 14.
 11. Branca, M., Giorgi C., Ciotti M., Santini D., Di Bonito L., Costa S., Benedetto A., Bonifacio D., Di Bonito P., **Paba P.**, Accardi L., Mariani L., Syrjanen S., Favalli C., Syrjanen K. On behalf of the HPV-PathogeneISS Study Group. Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human

papillomavirus (HPV) or virus persistence after treatment of CIN. *Anticancer Research* 2006 Mar-Apr;26(2b):1543-56.

12. Branca, M., Giorgi C., Ciotti M., Santini D., Di Bonito L., Costa S., Benedetto A., Bonifacio D., Di Bonito P., **Paba P.**, Accardi L., Mariani L., Syrjanen S., Favalli C., Syrjanen K. On behalf of the HPV-PathogeneISS Study Group. Down-regulation of E-cadherin is closely associated with progression of cervical intraepithelial neoplasia (CIN), but not with high-risk human papillomavirus (HPV) or disease outcome in cervical cancer. *European Journal of Gynaecological Oncology* 2006; 27(3):215-23.
13. Branca, M., Giorgi C., Ciotti M., Santini D., Di Bonito L., Costa S., Benedetto A., Bonifacio D., Di Bonito P., **Paba P.**, Accardi L., Mariani L., Ruutu M., Syrjanen S., Favalli C., Syrjanen K. On behalf of the HPV-PathogeneISS Study Group. Upregulation of nuclear factor-kappaB (NF-kappaB) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus or disease outcome in cervical cancer. *Diagn Cytopathol.* 2006 Aug; 34(8):555-63.
14. Natoli S., Ciotti M., **Paba P.**, Testore GP., Palmieri G., Orlandi A., Sabato AF., Leonardis F. A novel mutation of varicella-zoster virus associated to fatal hepatitis. *J Clin Virol.* 2006 Sep;37(1):72-4.
15. Branca, M., Giorgi C., Ciotti M., Santini D., Di Bonito L., Costa S., Benedetto A., Bonifacio D., Di Bonito P., **Paba P.**, Accardi L., Mariani L., Ruutu M., Syrjanen S., Favalli C., Syrjanen K. On behalf of the HPV-PathogeneISS Study Group. Over-expression of topoisomerase IIalpha is related to the grade of cervical intraepithelial neoplasia (CIN) and high-risk human papillomavirus (HPV), but does not predict prognosis in cervical cancer or HPV clearance after cone treatment. *Int J Gynecol Pathol.* 2006 Oct;25(4):383-92.
16. Branca M., Giorgi C., Ciotti M., Santini D., Di Bonito L., Costa S., Benedetto A., Bonifacio D., Di Bonito P., **Paba P.**, Accardi L., Mariani L., Ruutu M., Syrjanen S., Favalli C., Syrjanen K. Upregulation of telomerase (hTERT) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus, virus persistence, or disease outcome in cervical cancer. *Diagn Cytopathol.* 2006 Nov;34(11):739-748.

17. Branca, M., Ciotti M., Giorgi C., Santini D., Di Bonito L., Costa S., Benedetto A., Bonifacio D., Di Bonito P., **Paba P.**, Accardi L., Syrjanen S., Favalli C., Syrjanen K. Up-regulation of proliferating cell nuclear antigen (PCNA) is closely associated with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer. *Eur J Obstet Gynecol Reprod Biol.* 2006 Nov 10
18. Benedetto A., Giuliani L., **Paba P.**, Favalli C., Ciotti M. Evaluation of viral and cellular factors to assess the risk of oncogenesis by human papillomavirus. *Res. Adv. In Virology 2, 2007.*
19. Branca, M., Ciotti M., Giorgi C., Santini D., Di Bonito L., Costa S., Benedetto A., Bonifacio D., Di Bonito P., **Paba P.**, Accardi L., Syrjanen S., Favalli C., Syrjanen K. Predicting High-Risk Human Papillomavirus Infection, Progression of Cervical Intraepithelial Neoplasia, and Prognosis of Cervical Cancer With a Panel of 13 Biomarkers Tested in Multivariate Modeling. *Int J Gynecol Pathol.* 2008 Apr 27(2):265-273.
20. **Paba P.**, Bonifacio D., Di Bonito L., Ombres D., Favalli C., Syrjanen K., Ciotti M. Co-expression of HSV2 and *Chlamydia trachomatis* in human papillomavirus (HPV) positive cervical cancer and CIN lesions is associated with aberrations in key intracellular pathways. *Intervirology* 2008; 51(4):230-4.
21. Gaziev J, **Paba P**, Miano R, Germani S, Sodani P, Bove P, Perno CF, Marziali M, Gallucci C, Isgrò A, Paciaroni K, Roveda A, Simone MD, De Angelis G, Alfieri C, Lucarelli G. Late-onset Hemorrhagic Cystitis in Children after Hematopoietic Stem Cell Transplantation for Thalassemia and Sickle Cell Anemia: A Prospective Evaluation of Polyoma (BK) Virus Infection and Treatment with Cidofovir. *Biol Blood Marrow Transplant.* 2010; May;16: 662-671.
22. **Paba P**, Fabeni L, Ciccozzi M, Perno CF, Ciotti M. Performance evaluation of the COBAS/TaqMan HIV-1 v2.0 in HIV-1 positive patients with low viral load: a comparative study. *J Virol Methods.* 2011 May;173(2):399-402. Epub 2011 Mar 16
23. **Paba P**, Fabeni L, Perno CF, Ciotti M. Performance evaluation of the Artus hepatitis C virus QS-RGQ assay. *J Virol Methods.* 2012 Jan;179(1):77-80. Epub 2011 Oct 5.

24. Marchesi F, Giannotti F, Avvisati G, Petti MC, Pimpinelli F, **Paba P**, Dessanti ML, Cerretti R, Tirindelli MC, Picardi A, D'Andrea M, Spadea A, Ensoli F, Perno CF, Mengarelli A, Arcese W. The potential role of pre-transplant HBcIgG seropositivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: A study from the Rome Transplant Network. *Am J Hematol.* 2012 Feb;87(2):213-7. doi: 10.1002/ajh.22214. Epub 2011 Nov 11.
25. **Paba P**, Ascone C, Criscuolo AA, Marcuccilli F, Ciccozzi M, Sesti F, Piccione E, Perno CF, Ciotti M. Human papillomavirus molecular testing in women with low grade cervical lesions: experience from an italian hospital. *Anticancer Res.* 2012 Apr;32(4):1253-7
26. **Paba P**, Morosetti G, Criscuolo AA, Chiusuri V, Marcuccilli F, Sesti F, Piccione E, Perno CF, Ciotti M. Prevalence of human papillomavirus infection in italian and immigrant women. *Int J Immunopathol Pharmacol.* 2012 Oct-Dec;25(4):1055-62
27. Nucleotide polymorphisms in the 5'-UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype. Pollicita M, Cento V, **Paba P**, Perno CF, Ciotti M. *J Virol Methods.* 2013 Oct;193(1):205-8. doi: 10.1016/j.jviromet.2013.06.002. Epub 2013 Jun 19.
28. Screening of respiratory pathogens by Respiratory Multi Well System (MWS) r-geneTM assay in hospitalized patients. **Paba P**¹, Farchi F, Mortati E, Ciccozzi M, Piperno M, Perno CF, Ciotti M. *New Microbiol.* 2014 Apr;37(2):231-6. Epub 2014 Apr 1.
29. Microbiological Infections in Women With Cervical Cytological Reports of Atypical Squamous Cells of Undetermined Significance. **Paba P**, Criscuolo AA, Grazia Giancipoli R, Santi F, Ascone C, Sesti F, Piccione E, Perno CF, Favalli C, Ciotti M. *J Low Genit Tract Dis.* 2015 Jul;19(3):203-6.
30. Performance evaluation of AnyplexTMII HPV28 detection kit in a routine diagnostic setting: comparison with the HPV Sign[®] Genotyping Test. Marcuccilli F, Farchi F, Mirandola W, Ciccozzi M, **Paba P**, Bonanno E, Perno CF, Ciotti M. *J Virol Methods.* 2015 Jun 1; 217:8-13. doi: 10.1016/j.jviromet.2015.02.018. Epub 2015 Feb 25.

31. Nation-wide measure of variability in HCMV, EBV and BKV DNA quantification among centers involved in monitoring transplanted patients. Abbate I, Piralla A, Calvario A, Callegaro A, Giraldi C, Lunghi G, Gennari W, Sodano G, Ravanini P, Conaldi PG, Vatteroni M, Gaeta A, **Paba P**, Cavallo R, Baldanti F, Lazzarotto T; AMCLI – Infections in Transplant Working Group GLaIT. *J Clin Virol.* 2016 Sep; 82:76-83. doi: 10.1016/j.jcv.2016.07.001. Epub 2016 Jul 2.
32. Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Lazzarotto T, Chierighin A, Piralla A, Piccirilli G, Girello A, Campanini G, Gabrielli L, Costa C, Prete A, Bonifazi F, Busca A, Cairoli R, Colombo AA, Zecca M, Sidoti F, Bianco G, **Paba P**, Perno CF, Cavallo R, Baldanti F; AMCLI-GLaIT working group. *Biol Blood Marrow Transplant.* 2018 Aug;24(8):1699-1706. doi: 10.1016/j.bbmt.2018.03.005. Epub 2018 Mar 12.
33. Collaborative national multicenter for the identification of conversion factors from copies/mL to international units/mL for the normalization of HCMV DNA load. Sidoti F, Piralla A, Costa C, Scarasciulli ML, Calvario A, Conaldi PG, **Paba P**, Perno CF, Gaeta A, Antonelli G, Sodano G, Santangelo R, Sanguinetti M, Vatteroni ML, Barzon L, Palù G, Abbate I, Capobianchi MR, Piccirilli G, Lazzarotto T, Baldanti F, Cavallo R. *Diagn Microbiol Infect Dis.* 2019 Oct;95(2):152-158.

**Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base art. 13
del D. Lgs. 196/2003.**

Dott. Paba Pierpaolo